Incidence and outcomes of patients with atrial fibrillation and major bleeding complications: from the TREAT-AF study
- 28 September 2020
- journal article
- research article
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 62 (1) , 133-142
Abstract
Purpose Optimal stroke prevention strategies for patients with atrial fibrillation (AF) who experience a major bleed are poorly defined. We sought to estimate the effectiveness and safety of oral anticoagulation (OAC) represcription after an OAC contraindication. Methods TREAT-AF is a retrospective cohort study of patients with newly diagnosed AF (2004–2012), treated in the Veterans Health Administration. From this cohort, we identified patients with a contraindication to OAC after AF diagnoses, defined as incident intracranial bleeding, non-intracranial bleeding requiring hospitalization, or unrepaired cerebral aneurysm or aortic dissection. We used multivariate Cox proportional hazards to estimate the association of OAC prescription in the 90 days following OAC contraindication to ischemic stroke and rebleeding. Results Among 167,190 patients with newly diagnosed AF (70 ± 11 years, 1.7% female, CHA2DS2-VASc 2.7 ± 1.7), 19,285 patients (11.5%) had an incident bleed (n = 18,342) or an unrepaired cerebral aneurysm or aortic dissection (n = 943). For OAC-contraindicated patients with a CHA2DS2-VASc ≥2 (N = 16,194), OAC was represcribed in 4075 patients (25%) and was associated with a higher risk of non-intracranial bleeding (HR 1.49; 95% CI 1.37–1.61; p < 0.0001) but no difference in intracranial bleeding. There was a trend toward decreased stroke risk (HR 0.85; 95% CI 0.71–1.02; p 0.09). Conclusions Development of contraindication to OAC after diagnosis of AF is common (11.5%), with most events requiring hospitalization. OAC reinitiation was associated with non-intracranial bleeding risk, with a trend toward reduced stroke risk. These data suggest that stroke prevention approaches after major bleeding events could be beneficial if bleeding risk can be successfully mitigated.Keywords
Funding Information
- SentreHeart Inc
- U.S. Department of Veterans Affairs (Project Numbers SDR 02-237 and 98-004)
This publication has 37 references indexed in Scilit:
- Restarting Anticoagulation and Outcomes After Major Gastrointestinal Bleeding in Atrial FibrillationThe American Journal of Cardiology, 2014
- Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillationAmerican Heart Journal, 2013
- Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial FibrillationCirculation, 2013
- Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) studyAmerican Heart Journal, 2013
- Outcomes of Medicare Beneficiaries Undergoing Catheter Ablation for Atrial FibrillationCirculation, 2012
- A New Risk Scheme to Predict Warfarin-Associated HemorrhageJACC, 2011
- Apixaban in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial FibrillationChest, 2010
- Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial FibrillationCirculation, 2007
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006